Engineering E. coli for Enhanced Expression of Glycoconjugate Vaccines

Synthetic Glycan-based Glycomimetics & Inhibitors

Engineering <em>E. coli</em> for Enhanced Expression of Glycoconjugate Vaccines
November 26, 2025
Engineering E. coli for Enhanced Expression of Glycoconjugate Vaccines

On Apr 21, 2022, Kay et al., primarily from the London School of Hygiene & Tropical Medicine (LSHTM), published a paper in the journal Microbial Cell Factories titled "Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines". The paper details the successful refactoring of the Campylobacter jejuni N-linked […]

Read More >
Categories
Recent Posts
Engineering <em>E. coli</em> for Enhanced Expression of Glycoconjugate VaccinesEngineering E. coli for Enhanced Expression of Glycoconjugate Vaccines
Glyco-engineering ACE2 for Improved Potency as SARS-CoV-2 Decoy ReceptorGlyco-engineering ACE2 for Improved Potency as SARS-CoV-2 Decoy Receptor
Modifying the Glycocalyx of Melanoma Cells <em>via</em> Metabolic GlycoengineeringModifying the Glycocalyx of Melanoma Cells via Metabolic Glycoengineering
Engineering <em>Escherichia coli</em> for Highly Efficient Production of Lacto-<em>N</em>-triose IIEngineering Escherichia coli for Highly Efficient Production of Lacto-N-triose II
  • twitter
Our Services
Useful Links
Get In Touch
Copyright © CD BioGlyco. All Rights Reserved.
Top